Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 28:taac088. doi: 10.1093/jtm/taac088

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© International Society of Travel Medicine 2022. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Binding and neutralizing antibodies persist for 12 months after the second dose of the Covaxin/BBV152 (A) Surrogate Virus Neutralization for wild type and variant lineages of B.1.617.2 (Delta) B.1.617.2.1 (Delta Plus, India) B.1.351 (Beta, SA), B.1.1.7 (Alpha, UK) and B.1.1.529 (Omicron) at M0, M3, M6 and M12 following the first dose in all individuals and in those with prior infection and with no prior infection. Dotted line indicates the limit of detection (>20). (B) Values are the percentage of sera (at each time point) for which antibodies were detected for each variant and fold change increase of SARS-CoV-2 binding and neutralizing antibodies.